miR-181a-3p Inhibits Malignant Progression of Acute Lymphoblastic Leukemia Cells by Targeting SOCS5

doi:10.3870/j.issn.1672-8009.2026.02.010

Abstract

Abstract: Objective To investigate the effect of microRNA(miRNA)-181 a-3 p on the malignant progression of acute lymphoblastic leukemia(ALL)cells by targeting suppressor of cytokine signaling 5(SOCS5).Methods The expression levels of miR-181a-3p and SOCS5 in ALL cells were detected by RT-qPCR and Western blotting.MoIt4 cells were divided into 6 groups:anti-miR-NC group,anti-miR-181a-3p group,pcDNA group,PCDNA-SOCS5 group,anti-miR-181a-3p+si-NC group and anti-miR-181a-3p+si-SOCS5 group.RT-qPCR was used to detect the expression levels of miR-181a-3p and SOCS5.CCK8 and Transwell assay were used to detect cell proliferation,migration and invasion.Western blotting was used to detect the expression of SOCS5,CDK2,N-cadherin,E-cadherin and Vimentin.Dual luciferase gene reporter assay was used to detect the targeting relationship between miR-181a-3p and SOCS5.Results Compared with that in the PBMCS cells,the expression level of miR-181a-3p in the MoIt4 and Jurkat cells was increased(P<0.05),while the expression levels of SOCS5 mRNA and protein were decreased(P<0.05).Inhibition of miR-181a-3p or overexpression of SOCS5 decreased the proliferative activity,migration and invasion of MoIt4 cells,and the expression levels of N-cadherin,CDK2 and Vimentin,and increased the expression level of E-cadherin(P<0.05).miR-181a-3p negatively targeted SOCS5,inhibition of SOCS5 reversed the effect of miR-181a-3p on the proliferation,migration,invasion and epithelial-to-mesenchymal transition(EMT)in MoIt4 cells.Conclusion miR-181a-3p targets SOCS5 and negatively regulates the proliferation,migration,invasion and EMT of ALL cells.

Key words: miR-181a-3p, SOCS5, Acute lymphoblastic leukemia, Proliferation, Migration, Invade, Epithelial-to-mesenchymal transition

CLC Number:

R733

CHEN Jing, WU Sheng, WANG Yu, LIU Hua, XIA Nan, QIAN Jinfeng, SHA Yu. miR-181a-3p Inhibits Malignant Progression of Acute Lymphoblastic Leukemia Cells by Targeting SOCS5[J]. Journal of Medical Molecular Biology, 2026, 23(2): 179-185.

References

[1] DUFFIELD AS,MULLIGHAN C G,BOROWITZ M J.International consensus classification of acute lymphoblastic leukemia/lymphoma[J].Virchows Arch,2023,482(1):11-26.
[2] LAETSCH T W,MAUDE S L,RIVES S,et al.Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial[J].J Clin Oncol,2023,41(9):1664-1669.
[3] ZIĘTARA K J,LEJMAN J,WOJCIECHOWSKA K,et al.The importance of selected dysregulated microRNAs in diagnosis and prognosis of childhood b-cell precursor acute lymphoblastic leukemia[J].Cancers(Basel),2023,15(2):428.
[4] QIANG P,PAN Q,FANG C,et al.MicroRNA-181a-3p as a diagnostic and prognostic biomarker for acute myeloid leukemia[J].Mediterr J Hematol Infect Dis,2020,12(1):e2020012.
[5] LIU C W,PENG H Y,SIAO A C,et al.Resistin stimulates PC-3 prostate cancer cell growth through stimulation of SOCS3 and SOCS5 genes[J].Exp Biol Med(Maywood),2023,248(20):1695-1707.
[6] SHARMA N D,NICKL C K,KANG H,et al.Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia[J].Cancer Sci,2019,110(6):1931-1946.
[7] DAVIS K,SHEIKH T,AGGARWAL N.Emerging molecular subtypes and therapies in acute lymphoblastic leukemia[J].Semin Diagn Pathol,2023,40(3):202-215.
[8] BARRIOS-PALACIOS D,ORGANISTA-NAVA J,BALA-NDRÁN J C,et al.The role of miRNAs in childhood acute lymphoblastic leukemia relapse and the associated molecular mechanisms[J].Int J Mol Sci,2023,25(1):119.
[9] COLANGELO T,PANELLI P,MAZZARELLI F,et al.Extracellular vesicle microRNAs contribute to Notch signaling pathway in T-cell acute lymphoblastic leukemia[J].Mol Cancer,2022,21(1):226.
[10] TSOTRIDOU E,GEORGIOU E,TRAGIANNIDIS A,et al.miRNAs as predictive biomarkers of response to treatment in pediatric patients with acute lymphoblastic leukemia[J].Oncol Lett,2023,27(2):71.
[11] EDWARDSON M A,SHIVAPURKAR N,LI J,et al.Expansion of plasma MicroRNAs over the first month following human stroke[J].J Cereb Blood Flow Metab,2023,43(12):2130-2143.
[12] FOULADI H,EBRAHIMI A,DERAKHSHAN S M,et al.Over-expression of miR-181a-3p in serum of breast cancer patients as diagnostic biomarker[J].Mol Biol Rep,2024,51(1):372.
[13] WANG L H,SUN Y H,LIU H,et al.β-Sitosterol attenuates anlotinib resistance in non-small cell lung cancer cells by inhibiting miR-181a-3p/SHQ1 signaling[J].Chem Biol Drug Des,2024,103(3):e14493.
[14] LV X M,LI J B,YUN X,et al.miR-181a-5p,an inducer of Wnt-signaling,facilitates cell proliferation in acute lymphoblastic leukemia[J].Oncol Rep,2017,37(3):1469-1476.
[15] 王旭颖,荆明箴,余谨,等.miR-181a-5p和BACH2表达对白血病CCRF-CEM细胞凋亡和侵袭的影响[J].吉林大学学报(医学版),2023,49(04):840-849.
WANG X Y,JING M Z,YU J,et al.Effects of miR-181a-5p and BACH2 expressions on apoptosis and invasion of leukemic CCRF-CEM cells[J].J Jilin Univ Med Ed,2023,49(4):840-849.
[16] 李蒙,吴玖斌,张培彤.E-钙黏蛋白、N-钙黏蛋白及波形蛋白在肿瘤转移中应用的研究进展[J].肿瘤研究与临床,2016,28(2):132-136.
LI M,LI M,LI M.Research progress of application of E-cadherin,N-cadherin and vimentin in tumor metastasis[J].Cancer Res Clin,2016,28(2):132-136.
[17] LEE S W,LIU C W,HU J Y,et al.Suppressors of cytokine signaling in tuberculosis[J].PLoS One,2017,12(4):e0176377.
[18] 卜文超,曾宪智,关云茜,等.SOCS基因家族在肝细胞癌中的表达及生物信息学分析[J].山东第一医科大学(山东省医学科学院)学报,2022,43(10):740-747.
BU W C,ZENG X Z,GUAN Y Q,et al.Expression and bioinformatics analysis of SOCS gene family in hepatocellular carcinoma[J].J Shandong First Med Univ Shandong Acad Med Sci,2022,43(10):740-747.
[19] SANCHEZ-MEJIAS A,KWON J,CHEW X H,et al.A novel SOCS5/miR-18/miR-25 axis promotes tumorigenesis in liver cancer[J].Int J Cancer,2019,144(2):311-321.
[20] FAN G,JIAO J,SHEN F,et al.Long non-coding RNA HCG11 sponging miR-522-3 p inhibits the tumorigenesis of non-small cell lung cancer by upregulating SOCS5[J].Thorac Cancer,2020,11(10):2877-2886.
[21] TONIOLO P A,LIU S,YEH J E,et al.Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia[J].Oncotarget,2016,7(29):46301-46314.